Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.21 Billion KRW | -15.4% |
| 2022 | 2.61 Billion KRW | -32.43% |
| 2021 | 3.87 Billion KRW | 122.26% |
| 2020 | 1.74 Billion KRW | 4.9% |
| 2019 | 1.66 Billion KRW | -1.56% |
| 2018 | 1.68 Billion KRW | -48.11% |
| 2017 | 3.25 Billion KRW | -7.17% |
| 2016 | 3.5 Billion KRW | 48.91% |
| 2015 | 2.35 Billion KRW | 126.63% |
| 2014 | 1.03 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 586.62 Million KRW | 10.89% |
| 2024 Q1 | 526.23 Million KRW | -33.83% |
| 2023 Q4 | 795.27 Million KRW | 10.96% |
| 2023 Q3 | 716.73 Million KRW | 16.12% |
| 2023 Q2 | 617.25 Million KRW | 39.78% |
| 2023 FY | 2.21 Billion KRW | -15.4% |
| 2023 Q1 | 441.58 Million KRW | -39.24% |
| 2022 Q2 | 685.17 Million KRW | 8.31% |
| 2022 Q1 | 632.59 Million KRW | -45.85% |
| 2022 Q4 | 726.82 Million KRW | 27.11% |
| 2022 Q3 | 571.81 Million KRW | -16.55% |
| 2022 FY | 2.61 Billion KRW | -32.43% |
| 2021 Q3 | 724.38 Million KRW | -43.42% |
| 2021 Q2 | 1.28 Billion KRW | 83.09% |
| 2021 Q4 | 1.16 Billion KRW | 61.28% |
| 2021 FY | 3.87 Billion KRW | 122.26% |
| 2021 Q1 | 699.24 Million KRW | 104.16% |
| 2020 Q4 | 342.49 Million KRW | -33.89% |
| 2020 Q3 | 518.04 Million KRW | 4.03% |
| 2020 Q2 | 497.98 Million KRW | 29.81% |
| 2020 Q1 | 383.61 Million KRW | -8.57% |
| 2020 FY | 1.74 Billion KRW | 4.9% |
| 2019 FY | 1.66 Billion KRW | -1.56% |
| 2019 Q4 | 419.56 Million KRW | 24.22% |
| 2019 Q3 | 337.76 Million KRW | -26.04% |
| 2019 Q2 | 456.65 Million KRW | 2.22% |
| 2019 Q1 | 446.73 Million KRW | -7.38% |
| 2018 Q3 | 214.25 Million KRW | -57.73% |
| 2018 Q4 | 482.34 Million KRW | 125.13% |
| 2018 Q1 | 483.57 Million KRW | 24.94% |
| 2018 Q2 | 506.8 Million KRW | 4.8% |
| 2018 FY | 1.68 Billion KRW | -48.11% |
| 2017 Q1 | 1.48 Billion KRW | 233.46% |
| 2017 Q3 | 793.58 Million KRW | 36.38% |
| 2017 Q2 | 581.88 Million KRW | -60.91% |
| 2017 Q4 | 387.05 Million KRW | -51.23% |
| 2017 FY | 3.25 Billion KRW | -7.17% |
| 2016 Q3 | 872.42 Million KRW | 113.26% |
| 2016 Q4 | 446.43 Million KRW | -48.83% |
| 2016 Q2 | 409.09 Million KRW | -76.95% |
| 2016 Q1 | 1.77 Billion KRW | 259.64% |
| 2016 FY | 3.5 Billion KRW | 48.91% |
| 2015 Q2 | 462.06 Million KRW | 34.71% |
| 2015 FY | 2.35 Billion KRW | 126.63% |
| 2015 Q3 | 1.05 Billion KRW | 128.01% |
| 2015 Q4 | 493.4 Million KRW | -53.17% |
| 2015 Q1 | 342.99 Million KRW | 0.0% |
| 2014 FY | 1.03 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 136.814% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | 51.469% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 96.093% |
| Bioneer Corporation | 199.25 Billion KRW | 98.889% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 94.492% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -51.917% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -4.316% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 99.133% |
| Medy-Tox Inc. | 128.16 Billion KRW | 98.273% |
| Peptron, Inc. | 1.14 Billion KRW | -94.063% |
| Amicogen, Inc. | 51.51 Billion KRW | 95.703% |
| Genexine, Inc. | 387.48 Million KRW | -471.233% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | 66.935% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | 87.563% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 92.905% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 98.786% |
| SillaJen, Inc. | 1.45 Billion KRW | -51.944% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | 91.673% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 84.653% |
| Genomictree Inc. | -1.03 Billion KRW | 313.119% |
| MedPacto, Inc. | -1.83 Billion KRW | 220.777% |
| D&D Pharmatech | 18.67 Billion KRW | 88.149% |
| EASY BIO,Inc. | 50.88 Billion KRW | 95.65% |
| GI Innovation, Inc. | 1.98 Billion KRW | -11.26% |